- H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc ELOX to $1 from $2 and reiterated a Neutral rating.
- Analyst Andrew Fein says the ELX-02 top-line data "raises more questions than answers."
- Despite the "seemingly positive narrative put forward for the top-line data from ELX-02's Phase 2 top-line readout, we remain unconvinced," Fein tells investors in a research note.
- Related Link: Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors.
- Price Action: ELOX shares are down 12.40% at $0.76 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: BiotechNewsPenny StocksShort IdeasHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
